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Abstract
Objective: Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play 
important roles in angiogenesis of different developmental mechanisms such as wound 
healing, embryogenesis and diseases, including different types of cancer. VEGFR2 is as-
sociated with cell proliferation, migration, and vascular permeability of endothelial cells. 
Blocking VEGF and its receptors is suggested as a therapeutic approach to prevent tumor 
growth. In this study, we aim to block VEGF signaling via small interfering RNA (siRNA) 
inhibition of VEGFR2.         
Materials and Methods: In this experimental study, we used the RNA interference (RNAi) 
mechanism to suppress expression of the VEGFR2 gene. We conducted the 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay, real-time polymerase 
chain reaction (PCR), Western blot, and flow cytometry analyses of VEGFR2 expression. 
Results: Real-time PCR and Western blot results showed that VEGFR2 expression 
significantly downregulated. This suppression was followed by inhibition of cell prolifera-
tion, reduction of viability, and induction of apoptosis in the cancer cells.                       
Conclusion: These findings suggest that VEGFR2 has a role in cell proliferation and 
tumor growth. Accordingly, it is suggested that VEGFR2 can be a therapeutic target 
for controlling tumor growth and proliferation.            
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Introduction
Vascular endothelial growth factor (VEGF) and 
its receptors are central regulators of angiogenesis 
during wound healing, reproduction, organ devel-
opment, and embryogenesis as well as different 
diseases such as cancer and inflammatory diseases 
(1, 2). They are secreted from glycoproteins that 
act as vital survival factors for endothelial cells 
and mediate cell proliferation, vascular permeabil-
ity, and migration (3, 4). The biological function 
of VEGF is mainly mediated via interaction with 
its receptors that belong to the family of tyrosine 
kinases-VEGFR1 (FLT1), VEGFR2 (KDR) and 
VEGFR3 (5). Although both VEGFR1 and VEG-
FR2 are found in endothelial cells, VEGFR1 is ex-
pressed in macrophages, hematopoietic stem cells, 
and tumor cells such as lung, breast, and pancreat-
ic cancers, as well as hematopoietic malignancies 
(6). VEGFR1 has been well-described as a key 
regulator of migration as well as VEGFR2 signal-
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ing. VEGFR1 seems to be associated with acceler-
ated proliferation of transformed cells and plays an 
important role in malignant cell growth (7). It has 
been shown that VEGFR2 induces expression of 
growth factors in liver sinusoidal endothelial cells 
(8). VEGFR2 expression in certain cancers such as 
breast cancer showed a significant relation to high 
risk for metastasis and relapse. Hence, it is consid-
ered a marker for breast tumor aggressiveness (9).
Recent studies show that VEGF and its receptors 
are crucial molecules in induction or inhibition of 
angiogenesis and growth of  tumor cells (10). High 
level expression of VEGF stimulates angiogene-
sis while applying monoclonal antibodies inhibit 
or degrade VEGF and  suppress the angiogenesis 
process (11). These findings highlight the issue 
that the VEGF pathway may be an important ther-
apeutic target. Results from clinical trials using 
an aptamer (12) or an antibody fragment (13) that 
bind VEGF have already supported this concept. 
Another strategy to antagonize VEGF is to block 
the VEGFRs. A remarkable advantage of this ap-
proach is simultaneously blocking multiple VEGF 
family members (14).
RNA interference (RNAi), a fundamental bi-
ological process by which cells regulate gene 
expression, acts through complementary base-
pairing with target mRNA and retrieves cellu-
lar RNases which in turn degrade mRNA tran-
scripts (15). The RNAi strategy has developed 
rapidly from a basic scientific discovery to a 
powerful research tool and more recently, to a 
promising therapeutic approach (16). RNAi is 
now routinely used to evaluate gene function 
both in vitro and in vivo. Many innovative stud-
ies have reported the use of RNAi to investi-
gate potential drug targets (17). Specific gene 
knockdown that can be achieved using RNAi as 
a therapeutic approach have made such thera-
pies very attractive to many scientists as cure 
for different diseases. Small interfering RNAs 
(siRNAs) provide a useful means to selectively 
reduce the amount of mRNA transcripts and 
probe the function of gene products (18). In our 
previous study we have used siRNA to reduce 
VEGFR1 expression in vitro (19-22). In the pre-
sent study, we aimed to specifically downregu-
late VEGFR2 expression in the ATCC® CRL-
1739™ human gastric carcinoma cells (AGS) 
using synthetic siRNA. 
Materials and Methods
In this experimental study, we used the RNAi 
mechanism to suppress expression of the VEGFR2 
gene. This project conducted according to approv-
al from the Baqiyatallah University of Medical 
Sciences Ethical Committee. 
Materials
RPMI-1640, fetal bovine serum (FBS), penicil-
lin-streptomycin (Pen/Strep), and trypsin enzyme 
were purchased from Gibco (USA). RNA extrac-
tion, cDNA synthesis and polymerase chain reac-
tion (PCR) purification kits were obtained from 
Roche, Germany. Restriction enzymes were pur-
chased from Jena Bioscience.
Methods
Small interfering RNA design
Anti-VEGFR2 siRNAs were purchased from 
Takapuzist Gene Molecular Biotechnology Co., Ltd. 
(Iran). The siRNA was designed using an AsiDe-
signer  (Bioinformatics Research Center, KRIBB) 
to target VEGFR2 at the 5´-TAGCTGGGAATAG-
TAAAGC-3´ sequence. Sense and antisense sequenc-
es were as follows for siRNA1: Si-sense1: 5´-GC-
UUUACUAUUCCCAGCUA-3´; and Si-antisense1: 
5´-UAGCUGGGAAUAGUAAAGC-3´. Each siR-
NA was re-suspended in double distilled water and 
the stock solutions (20 μmol/L) were stored at 4˚C.
Cell culture 
AGS cells (Pasteur Institute, Iran) were grown 
in RPMI-1640 medium that contained 10% FBS. 
Cells were incubated in a humidified 5% CO2 incu-
bator at 37˚C for 48 hours. Viability of cells were 
examined by trypan blue, after which they were 
incubated under hypoxic conditions (3% O2, 5% 
CO2, 92% N2) for 24 hours to upregulate expres-
sion of the target gene.
Transfection of small interfering RNA  
AGS cells were cultured in RPMI-1640 medi-
um. Briefly, 4×105 cells were seeded onto six-well 
plates that contained antibiotic-free Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco, USA). 
Plates were incubated overnight at 37˚C. For each 
well, 2 μl of siRNA (0.1 nmol/L) was mixed with 
50 μl of DMEM. This mixture was then combined 
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with a solution of 1 μl lipofectamine® 2000 (Inv-
itrogen, USA) in 50 μl DMEM and incubated for 
20 minutes at room temperature. Finally, a mixture 
that had a final concentration of 20 pmol/L for each 
siRNA was applied to the cells. After incubation 
for 4 hours at 37˚C, we replaced the media with 
fresh RPMI-1640 medium supplemented with se-
rum and Pen/Strep (100 µg/ml). All tests were per-
formed in triplicate at 24, 48, and 72 hours after 
siRNA transfection.
Cell viability assay   
The cells were seeded onto 96-well plates at a 
density of approximate 2×104 cells per well and 
incubated at 37˚C in a 5% CO2 humid incubator for 
24 hours. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay (23) 
was used to determine cell viability at 24, 48, and 
72 hours after the cells were transfected with anti-
VEGFR2 siRNA. We measured absorbance at 570 
nm using a Quant Universal Microplate Spectro-
photometer (BioTek, Winooski, VT).
Colony formation assay   
In the colony formation assay, we seeded the 
cells onto a 12-well plate at a density of 300 single 
cells per well after transfection. The medium was 
changed every three days. After approximately 10 
days, most clones contained more than 50 cells. 
The clones were subsequently washed with 1X 
phosphate-buffered saline (PBS) and stained with 
crystal violet for approximately 5 minutes. Finally, 
the clones were imaged and quantified. The colony 
formation rate was calculated as the (number of 
clones)/(number of seeded cells)×100.
RNA extraction and cDNA synthesis     
Total RNA was extracted from the cells using the 
RNXTM plus solution (Cinnagen, Iran) according 
to the manufacturer’s instructions. Briefly, 2 µg 
of total RNA was reverse transcribed and cDNA 
synthesized using a cDNA synthesis kit (Roche 
Co., Germany), according to the manufacturer’s 
instructions. The reverse transcription reaction for 
first strand cDNA synthesis was performed with 
3-5 µg of purified total RNA with RevertAid™ 
Reverse Transcriptase (Fermentas, Canada) using 
oligo (dT)18 in a 20 µl total reaction mixture, ac-
cording to the manufacturer’s instructions.
Real-time polymerase chain eaction analysis of 
VEGFR2 mRNA levels     
mRNA expression levels of genes were estimated 
with the appropriate primers. The relative expres-
sion of each gene was assessed and compared to the 
housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) with specific primers. All 
primers were designed using Primer Express® soft-
ware (Applied Biosystems, USA). Amplifications 
were carried out using the following primers for 
VEGFR2:
F: 5´-CACTGGTTGTACCTCAGCAC-3´ 
R: 5´-CGTACCAGAAGACACTTCGT-3´
GAPDH:
F: 5´-GTGAACCATGAGAAGTATGACAA-3´ 
R: 5´-CATGAGTCCTTCCACGATAC-3´.
Quantitative RT-PCR was performed using the 
7500ABI system (Applied Biosystems, USA) in 
final reaction volumes of 20 µl with 20 ng cDNA, 
10 µl of SYBR Green I master mix (Takara, Ja-
pan) and 200 nM of forward and reverse primers, 
according to the manufacturer’s instructions. The 
PCR reaction was performed as follows: initial 
denaturation of templates at 95˚C for 5 minutes, 
followed by 35 cycles of denaturation at 95˚C for 
15 seconds, and annealing/extension at 60˚C for 
30 seconds. Specificity of PCR products was ex-
amined by running on a 2% agarose gel to verify 
their size and dissociation curve analysis. We used 
serially diluted cDNA to obtain a standard curve 
and amplification efficiency for each primer of the 
gene transcript. For all gene expression analyses, 
the appropriate negative controls that contained no 
template controls were subjected to the same pro-
cedure in order to exclude or detect any possible 
contamination. All tests were repeated three times.
Western blot analysis     
Western blot analysis was carried out for VEG-
FR2 using an anti-VEGFR2 antibody (Abcam Co.) 
as the primary antibody. The cells were collected 
and lysed by RIPA lysis buffer (Sigma-Aldrich 
Corp., St. Louis, MO, USA). Total protein was 
extracted and stored at -80˚C. The extracts were 
then mixed with 6× sodium dodecyl sulfate (SDS) 
buffer and boiled for 4 minutes. Samples were sep-
arated by 10% SDS-polyacrylamide gel electro-
phoresis and transferred to a polyvinylidene fluo-
ride (PVDF) membrane. Membranes were blocked 
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with 5% (w/v) skim milk in PBS that contained 
0.1% Tween-20 for 1 hour at room temperature, 
washed with PBS, and probed with primary anti-
bodies overnight at 4˚C. Membranes were washed 
again with PBS and incubated at room tempera-
ture with horseradish peroxidase (HRP)-conjugat-
ed anti-rabbit secondary antibodies (Abcam Co., 
UK) for 1 hour. Proteins were visualized with an 
enhanced chemiluminescence detection kit (Am-
ersham Bioscience, Buckinghamshire, England). 
Actin (a goat polyclonal antibody) was used as the 
internal control.
Apoptosis assay      
The number of apoptotic cells was calculated 
with an Annexin-V-PI detection kit (Abcam Co., 
UK). AGS cells at a density of 2×105 were cul-
tured, suspended in RPMI1640 with 10% FBS, 
and seeded in a 24-well flat-bottomed plate, then 
incubated for 24 hours at 37˚C. Cells were then 
transfected by anti-VEGFR2 siRNA. After incu-
bation for 48 hours, the cells were collected and 
washed with PBS, after which PI and annexin V 
were added directly to the cell suspension in the 
binding buffer that consisted of 10 mM HEPES, 
140 mM NaCl, and 2.5 mM CaCl2 at pH=7.4.  The 
cells were incubated in the dark for 15 minutes at 
37˚C, followed by flow cytometry analysis.
Statistical analysis     
The results were analyzed with one-way ANO-
VA followed by the t test using the Graphpad 
Prism 5.0 program and SPSS (SPSS, Chicago, IL, 
USA). A P≤0.05 was considered significant. Data 
were shown as mean ± SD.
Results
Cell viability assay  
We conducted the MTT assay to evaluate the ef-
fect of anti-VEGFR2 siRNA on viability of AGS 
cancer cells. AGS cells were transfected with anti-
VEGFR2 siRNA, then incubated for 24, 48, and 
72 hours. The MTT assay results showed that us-
ing specific siRNA against VEGFR2 reduced the 
viability of AGS cells compared with the control 
group in a time-dependent manner (Fig.1). The 
results showed the cytotoxicity of VEGFR2 sup-
pression to AGS cancer cells. Untreated cells were 
used as the control. 
Fig.1: Survival ratios of AGS cells treated with anti-vascular en-
dothelial growth factor 2 (anti-VEGFR2) small interfering RNA 
(siRNA). The 80% confluent cell cultures were treated with siR-
NA. Cell viability significantly reduced in a time-dependent man-
ner. At 48 hours after treatment more than 50% of cells died. 
Results are the means of three independent experiments by the 
MTT assay (P≤0.05). 
Colony formation assay       
In order to further elucidate the effect of anti-
VEGFR2 siRNA AGS cell growth, we performed 
the colony formation assay at 24, 48, and 72 hours. 
Figure 2 shows that the colony formation rate of 
AGS cells transfected with anti-VEGFR2 siRNA 
reduced to approximately 65% compared to the 
control cells. These results showed that anti-VEG-
FR2 siRNA impaired proliferation of the AGS cell 
line. All experiments were performed in triplicate.
Fig.2: Colony formation ratio of AGS cells after transfection with 
anti-vascular endothelial growth factor 2 (anti-VEGFR2) small in-
terfering RNA (siRNA) after 72 hours. The data showed significant 
reduction in colony formation. All experiments were performed 
in triplicate. Values are mean ± SD.
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Real-time polymerase chain reaction for 
VEGFR2 mRNA        
The effect of anti-VEGFR2 siRNA transfec-
tion on VEGFR2 gene expression was analyzed 
by quantitative real-time PCR after 24, 48, and 
72 hours. Total RNA was extracted from both 
transfected and control cells after treatment with 
siRNAs against VEGFR2. GAPDH was used as 
a reference to compare gene expression in dif-
ferent cells. Real-time PCR analysis revealed 
that the expression level of VEGFR2 decreased 
significantly in cells treated with specific siR-
NAs compared to control cells without siRNA 
treatment (Fig.3). The results indicated that anti-
VEGFR2 application successfully decreased the 
VEGFR2 mRNA level.
Fig.3: Quantitative analysis of vascular endothelial growth factor 
2 (VEGFR2) gene expression levels downregulated in AGS cells 
72 hours after treatment with anti-VEGFR2 small interfering RNA 
(siRNA). Each real-time polymerase chain reaction (PCR) analysis 
was carried out at least in triplicate. Data are the fold change in 
relative expression compared with glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) based on the comparative Ct (2-ΔΔCt) 
method. Values are shown as mean ± SD.
Western blot analysis
Total protein was extracted from cells and analyzed 
on sodium dodecyl sulfate-page (SDS-PAGE), fol-
lowed by Western blot analysis to measure VEGFR2 
protein levels in AGS cells after 24, 48, and 72 hours. 
As Figure 4 shows, un-transfected cells expressed a 
19 kDa VEGFR2 band while cells transfected with 
siRNAs against VEGFR2 showed significant reduc-
tion of VEGFR2 protein level compared to the con-
trol group. This indicated that use of anti-VEGFR2 
siRNA specifically targeted VEGFR2 mRNA and in-
fluenced its protein production. We used β-actin as the 
positive control in this experiment.
Fig.4: Analysis of the small interfering RNA (siRNA) effect on 
vascular endothelial growth factor 2 (VEGFR2) protein expres-
sions in AGS cells according to Western blot after 72 hours. Lane 
1; β-actin as the positive control, Lane 2; Protein marker, Lane 
3; Negative control without protein loading, Lane 4; AGS cells 
without siRNA treatment, and Lane 5; AGS cells transfected with 
siRNA. As shown, a 19 KDa protein expressed in transfected cells 
without siRNA treatment. Transfection with siRNA significantly 
reduced VEGFR2 protein levels.
Apoptosis assay 
We used an Annexin-V-PI kit to measure the num-
ber of apoptotic cells after transfection with siRNA 
against VEGFR2 after 24, 48, and 72 hours. Cells 
seeded in a 24-well plate were transfected with anti-
VEGFR2 siRNA. Cells were subsequently treated 
with Annexin V-FITC and PI, then analyzed by flow 
cytometer. Figure 5 shows that the number of apop-
totic cells significantly reduced following transfection 
with siRNA compared with the control group. Total 
apoptosis increased from approximately 2.93% (Q2 
as early apoptotic) to 27.0% (Q3 as late apoptotic) 
in the treated group compared to the control group, 
which supported the cell viability assay results. 
 CELL JOURNAL(Yakhteh), Vol 18, No 3, Oct-Dec (Autumn) 2016 386
Inhibition of Cancer Cell Proliferation Using Anti-VEGFR2 siRNA
Fig.5: Flow cytometry analysis of AGS cells stained with Annexin V-FITC and PI. A. Untreated cells were used as controls and B. Cells 
underwent apoptosis induced by anti-vascular endothelial growth factor 2 (anti-VEGFR2) small interfering RNA (siRNA) after 72 hours. 
Diagrams Q1 to Q4 represent necrotic, early apoptotic, late apoptotic and live cells, respectively. Treated cells significantly increased in 
the rate of early and late apoptosis compared with the control.
Discussion
The key roles of VEGF and its receptor VEG-
FR1 and VEGFR2 in tumor angiogenesis and 
tumor growth are well-established. Activation of 
VEGFR2 leads to the activation of downstream 
signaling pathways (24). In contrast, the func-
tion of VEGFR1 is still poorly determined (25). 
VEGFR1 has been shown to be associated with 
tumor growth, tumor cell activation, and metasta-
sis (26). Studies reported VEGFR1 expression in 
many tumors including breast, lung, and gastric 
cancers (27-29). Upregulation of serum VEGFR1 
has been shown in gastric cancer patients (30). 
Blocking VEGF is an important way to control an-
giogenesis and cancer growth. It was previously 
demonstrated that VEGF, VEGFR1 and VEGFR2 
co-expressed in gastric adenocarcinoma MGC803 
cells as well as eight gastric cancer cell lines that 
included AGS-1, RF-1 and RF-48, as well as gas-
tric tumor specimens (31-35).
There are different anti-VEGF agents used to 
control angiogenesis include chemicals and anti-
bodies (35, 36). Inhibition of its receptors is an-
other strategy to antagonize VEGF which in turn 
can simultaneously block several VEGF family 
members. VEGFRs have been considered for can-
cer therapy and production of anti-cancer drugs 
(37). Several VEGFR inhibitors have been devel-
oped such as SU6668, ZD6474, PTK787 com-
pounds and mono-clonal antibodies (38). Hwang 
et al. (30) reported that blockage of VEGFR1 and 
VEGFR2 with concomitant paclitaxel increased 
cell cytotoxicity of TUBB3-expressing gastric 
cancer cells. They demonstrated that AGS cell cy-
totoxicity was more obvious when cells were treat-
ed simultaneously with paclitaxel, anti-VEGFR1, 
and anti-VEGFR2. From these results, we sug-
gested that the AGS cells expressed VEGFR1. In 
the present study, we suppressed the expression of 
VEGFR2 in the AGS cell line using anti-VEGFR2 
siRNA. Real-time PCR analysis of mRNA levels 
showed that siRNA efficiently decreased VEGFR2 
expression compared to control cells. Western 
blot analysis showed that after the use of siRNA 
against VEGFR2, its protein level significantly re-
duced compared to the control group. The colony 
formation assay and MTT assay results showed 
that downregulation of VEGFR2 inhibited cancer 
cell growth and significantly reduced cell viabil-
ity. Also, apoptosis assay results indicated signifi-
cant induction of cell death. However, in addition 
A B
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to inhibition of cell growth, our results suggested 
that suppression of VEGFR2 could significantly 
drive cells to apoptosis. Some investigators have 
reported that VEGFR2 suppression is not adequate 
to hinder tumor growth without the combined in-
hibition of VEGFR2 (39, 40). Of note, VEGFR2 
signaling within tumor cells was previously shown 
to regulate growth and survival of several mouse 
tumor models and cell lines (31, 41). Some reports 
suggested a possible role for VEGFR2 in survival 
and growth of cancer cell lines such as pancreatic 
and colorectal cancer cell lines (42). Inhibition 
of VEGFR2 signaling using hyper methylation 
showed tumor growth inhibition and decreased 
survival of cancer cells in some tumor models (35). 
Overall, the current research indicated that 
blocking VEGFR2 using RNAi suppressed cell 
proliferation in AGS cells, as well as induction of 
apoptosis in AGS cells.
Conclusion
Blocking VEGF and its receptors have been pro-
posed as a therapeutic approach for inhibition of 
cancer growth. In the present study, we used RNAi 
to downregulate expression of the VEGFR2 gene 
using specific siRNAs in AGS cells. The results 
showed that suppression of VEGFR2 inhibited 
AGS cell proliferation and drove them to apoptosis. 
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